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Anthrax is a serious bacterial infection with a 
particularly high mortality in its gastrointestinal, 
pulmonary, and meningitic forms with a world­
wide distribution, although it is most common 
in the developing world. Gastrointestinal and 
pulmonary anthrax results in death within hours 
or a few days of the onset of serious symptoms 
and the diagnosis is usually made post-mortem. 
Treatment of wild type anthrax is usually with 
penicillin in high dose. The production of an­
thrax for large scale bioterrorism is difficult and 
requires sophisticated facilities. There is a 
greater risk that anthrax used as a bioterrorist 
weapon w ill be antibiotic resistan t and 
ciprofloxacin is a more appropriate antibiotic 
choice until the antibiotic sensitivity of the an­
thrax strain being deployed becomes known. 
Post exposure prophylaxis should be continued 
for two months due to the long delay that some­
times occurs before spores germinate once within 
the human host. A live vaccine is available but 
requires a large number of injections and its use 
is largely limited to military personnel.
Introduction
In early October last year I was on my way back 
to Edinburgh from a meeting in London. A sig­
nalling failure just outside Paddington station 
meant that a journey on the Heathrow Express 
extended from 15 to 75 minutes, during which 
time I watched the BBC News summary more 
times than I would have wished, particularly 
since the delay threatened my return that night 
to Edinburgh. BBC News majored on the 
bioterrorist outbreak of anthrax which was then 
in its early phases in the USA. The index case
became ill on October 2nd in Florida and died a 
few days later1. To my surprise a disease which 
I had treated several times at a teaching hospital 
in Tanzania 20 years previously was now appar­
ently of global interest. On my return to Edin­
burgh I offered to give a short presentation at 
the Grand Round at the Western General Hospi­
tal, since if Al Qaeda was responsible it was at 
least remotely possible that the UK, as the clos­
est ally of the USA, might also be a target. This 
paper is a direct result of that presentation and 
seeks to summarise what we know about anthrax, 
its clinical presentations and treatment, both in 
endemic and bioterrorist forms.
The causative organism and pathogenesis
Anthrax derives its name from the Greek word 
anthrakos meaning coal due to the appearance 
of a coal black centre in the lesion in the cutane­
ous form. Anthrax is caused by a gram positive, 
spore forming, toxin producing aerobic rod, Ba­
cillus anthracis. Although in vitro it grows as 
long chains, in the human host it appears as sin­
gle organisms or chains of 2 or 3 bacilli 1. The 
vegetative bacillus does not survive long in a pu­
trefying carcass, only 3-4 days at 25° C 2. Es­
caping bacilli at temperatures above 20°C form 
spores which may survive decades, but these are 
destroyed by dry heat of 150°C, boiling for 10 
minutes, and autoclaving. The toxin has three 
parts, of which two are important, an oedema 
factor and a lethal factor2. Lethal factor stimu­
lates the release of tumour necrosis factor and 
interleukin-1a contributing to sudden death2.
The lethal factor is a protease with a particular 
amino acid substrate which could be a target for
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the development of an inhibitor1. Infection is 
initiated after introduction of a spore through a 
break in the skin or mucosa and the vegetative 
form is germinated after ingestion by 
macrophages and may then pass to regional 
lymph nodes and the spleen. Extracellular mul­
tiplication then occurs with toxin production 2. 
Lethal factor is produced and released in a burst, 
causing fever, disorientation, coma, and death. 
In rhesus monkeys, inhaled spores are deposited 
in alveolar spaces and then transported to medi­
astinal lymph nodes where germination occurs 
up to 60 days later. It was this observation that 
has led to the recommendation that antibiotic 
prophylaxis should be continued for 60 days af­
ter inhalational exposure2.
Epidemiology of wild type anthrax
Anthrax has a worldwide distribution but is now 
most common in developing countries, princi­
pally in Africa and Asia. Historically, some out­
breaks have been massive. In 1945 an outbreak 
in Iran caused one million sheep deaths1, and 
between 1979 and 1985 an outbreak in Zimba­
bwe caused 10,000 human cases2. Even in de­
veloped nations anthrax has continued to cause 
problems. Between 1944 and 1994, the USA 
reported 224 cases, of which 18 were 
inhalational3. Occasional cases have surfaced 
elsewehere in the developed West, for instance 
in 1976 fatal pulmonary anthrax was contracted 
from bone meal fertiliser in the U K 4. Cutane­
ous anthrax occurred in a casual labourer in Lon­
don in 19965, and a Norwegian who skin-popped 
heroin in 2000 6. The annual total for cases 
worldwide is estimated at 20,000-100,000 2.
The anthrax bacillus as a bioterrorist weapon
The use of anthrax as a bioterrorist weapon was 
extensively reviewed only 2 years before the 
2001 outbreak by Inglesby in the Journal of the 
American Medical Association 1. There has been 
interest in anthrax as a weapon of war for many 
years. During WWII British scientists conducted 
experiments on Gruinard Island off the West 
coast of Scotland and several decades elapsed 
before it was successfully decontaminated. Aum 
Shinrikyo terrorists in Japan made at least eight 
unsuccessful attempts to release aerosols of an­
thrax spores before their more tragically ef­
fective release of sarin nerve gas in a Tokyo sub­
way in 1995. After the Gulf War, Iraq admitted 
producing and deploying weaponized anthrax in 
missiles, lending weight to the view that a clear 
threat remained, a threat which has now become 
all too obvious1.
A few litres of standard broth culture prepared 
in a kitchen can produce sufficient spores to in­
fect a few people if sent through the post. 
Lyophilising cultures into powder requires sim­
ple equipment, but ultra refining spores is nec­
essary if more extensive bioterrorism is planned. 
Particles need to be between 1-5 um 1 and elec­
trostatically neutral in order to avoid clumping 
M. This is probably beyond the ability of small 
groups and it has been estimated that for an at­
tack on an urban population of 5 million, the 
aerial discharge of 50 kg of highly refined spore- 
containing powder would be needed to cause 
250,000 cases 2.
The major experience with anthrax in 
bioterrorist form comes from Russia. In 1979 
accidental discharge into the atmosphere oc­
curred at a biological warfare research establish­
ment at Sverdlovsk. Precise figures are not avail­
able but it is thought that 100 inhalational cases 
may have occurred of which 66 were fatal, all 
aged over 24 years *. Cases in humans occurred 
up to 4 km and in animals up to 50 km from the 
factory site '. On the basis of experiments in 
primates the dose in humans causing 50% 
lethality is between 2500 and 55,000 spores 1 
and this amount is not visible to the naked eye.
The strain of anthrax used in bioterrorism in 
late 2001 in the USA was a derivative of Ames 
strain used worldwide by researchers, and first 
isolated from a dead animal in Ames, Iowa in 
the 1950s. Preliminary analysis suggested the 
presence of constitutive and inducible beta 
lactamases and for this reason treatment with 
penicillin, ampicillin or amoxicillin was not rec­
ommended 2. The CDC website does not give a 
clear total for the number of human cases asso­
ciated with this outbreak at the point of writing 
this paper in May 2002 but by 28th November 
2001 23 cases had been identified of which 11 
were inhalational and 12 cutaneous 1.
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Principal clinical manifestations
Cutaneous anthrax (Figures 1-4)
This occurs as the result of direct contact with 
viable organisms invading through a skin break. 
Person to person spread does occur but very 
rarely and has been documented as a result of 
sharing scrubbing brushes used during bathing-1. 
The cutaneous form is referred to as a malignant 
pustule, but this is a misnomer since there is no 
pus unless secondary bacterial infection occurs. 
The incubation period is 1-7 days, following 
which a pimple grows rapidly over 2-4 days. The 
initial itchy painless vesicle is 1-2cm in diam­
eter and filled with clear or serosanguinous fluid. 
As the vesicle enlarges satellite vesicles develop 
with impressive surrounding oedema. When the 
vesicle ruptures it forms an ulcer covered by a 
black eschar by day 4-5. Without the use of an­
tibiotics resolution occurs after 10 days and in 
80-90% of cases healing occurs without scar­
ring. Ulceration may still occur after antibiotic 
use and total resolution may take 2-6 weeks.
Figure 1. Facial cutaneous anthrax with marked 
oedema.
Figure 2. Facial ‘malignant pustule ’ with ery­
thema and oedema spreading down onto the an­
terior chest wall. The patient was hypotensive 
and febrile.
The differential diagnosis (see over) is wide and 
the list is based in part on the paper by Dixon et 
al published in 1999
Gastro-intestinal anthrax
This occurs as a result of eating infected meat 
and comprises 95% of cases with a mortality of 
only 1%. The incubation period is 1-7 days af­
ter ingestion, during which an eschar develops 
on the intestinal mucosa, usually in the terminal 
ileum or caecum but it may occur anywhere from 
the oropharynx downwards 3. Gross mesenteric 
lymphadenitis follows and perforation of the in­
testine may occur at the site of the eschar. Gastro­
intestinal anthrax is usually undiagnosed until 
too late. The clinical features are sudden onset 
of severe diffuse abdominal pain, nausea and 
vomiting and variably, watery or bloody diar­
rhoea may be present. On physical examination 
there will usually be fever, rebound tenderness, 
shock, and collapse, and ascites may be present 
after 2-4 days. Death occurs in a few hours or 
recovery may occur after 10-14 days.
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Above: Figure 3a. Marked oedema in cutane­
ous anthrax affecting the thigh. No clear malig­
nant pustule is seen. A BCG scar is present in 
the centre o f  the photograph.
Below: Figure 3b. Ulceration in the same p a­
tient during convalescence.
Above: Figure 4
One o f  four patients admitted to Kilimanjaro 
Christian Medical Centre, Tanzania in 1977. 
They had found a dead zebra, carried it to their 
village and cooked it over an open fire. The three 
patients who had eaten zebra meat developed 
severe abdominal symptoms suggestive o f  an 
intra-abdominal catastrophe and died in the sur­
gical department. This patient had marked cu­
taneous invasion o f  spores as a result o f  having 
carried the zebra on his right shoulder. He has 
oedema o f  the anterior chest wall, visible as nip­
ple oedema, and was severely hypotensive. He 
died four hours later.
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Table 1: Differential Diagnosis of Cutaneous Anthrax
Disease Causative organism
Ecthyma gangrenosum Pseudomonas aeroginosa
Rat bite fever Streptobacillus moniliformis
Ulceroglandular tularaemia Francisella tularensis
Plague Yersinia pestis
Rickettsial pox Rickettsia akari
Scrub typhus Rickettsia tsutsugamushi
Tick bite fever Rickettsia conorri and africae (Figures 5&6)
O rf Parapoxvirus (Figure 7)
Staphylococcal infection Staphylococcus aureus
Cutaneous TB Mycobacterium tuberculosis
Leprosy Mycobacterium leprae
Buruli ulcer Mycobacterium ulcerans
Spider bite Loxosceles reclusa19
Pulmonary anthrax
Pulmonary anthrax occurs as a result of the in­
halation of spore-laden dust. The incubation 
period is 1 -6 days. Prior to the 1960s in the USA, 
workers in goat hair mills were exposed to high 
concentrations of viable spores but there were 
few cases of inhalational anthrax. However 
when dispersed in the air as an aerosol anthrax 
spores can present a real hazard even long dis­
tances dow nw ind , as dem onstra ted  by the 
Sverdlovsk outbreak in 1979. Modal incubation 
is 10 days, but in the Sverdlovsk outbreak some 
cases occurred up to 6 weeks after accidental 
discharge. Longer incubation times probably 
occur with smaller inocula. During the first few 
days patients have no symptoms or ‘flu’ for a 
few days and then there is abrupt onset of chills, 
a strident cough, blood stained vomit due to hae- 
matogenous spread to the gut. dyspnoea and cya­
nosis, and on examination moist chest sounds 
and signs of systemic collapse. The spleen and Figure 5. Tick typhus lesion in visitor to Ten- 
axillary lymph nodes may be enlarged. A chest erife (Rickettsia conorii)
X-ray may show widened mediastinum, and
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blood culture becomes positive within 2-3 days 
o f the onset o f symptoms (sample chest X-rays 
can be down loaded from the CDC website). 
Death usually occurs in 2-3 days but milder cases 
occur with bronchitic symptoms.
Anthrax meningitis
This is rare, but may arise from any form o f the 
disease. It is characterised by blood stained CSF 
and the prognosis is poor. A few cases of recov­
ery have been recorded if antibiotics are com ­
bined with anti-toxin and prednisolone.
Laboratory diagnosis
This is usually by m icroscopy and culture. In 
cutaneous lesions gentle sam pling is recom ­
mended with a moist sterile applicator. Blood 
cultures become positive in 6-24 hours12, but may 
be negative if antibiotics have been given. The 
earliest that confirm ation could be expected 
would be 48 hours but if a laboratory has not 
been notified about the possibility of anthrax the 
diagnosis may be missed 12. In gastrointestinal 
or pulm onary anthrax death often precedes ac­
curate diagnosis. Dry nasal swabs allow detec­
tion of anthrax spores. Serological tests are not 
usually helpful. Anthrax ELIS As only rise in 
70-90% of convalescent patients1 . PCR is avail­
able in only a few centres.
Figure 6. Tick typhus lesion in visitor to Kruger 
Game reserve (Rickettsia africae)
Figure 7. O rf virus infection (D r Clifford Leen's 
patient)
Treatment for wild type anthrax
A n th ra x  is s e n s it iv e  to  p e n ic i l l in s ,  
fluoroquinolones, tetracyclines, chloram pheni­
col, gentam ycin, erythrom ycin, clindam ycin, 
vancomycin and first generation cephalosporins. 
Isolates o f natural strains are rarely resistant to 
penicillin, although resistance has been reported 
in India 1. There is some natural resistance to 
co trim o x azo le , second  g en era tio n  cep h a lo ­
sporins and aztreonam.
Varying advice is given for acutely ill cases in 
current textbooks, but initially benzyl penicillin 
should be given in a dose o f 2.4 G 4-6 hourly, 
initially iv for three to five days. Cutaneous sores 
becom e sterile in one to two days. Plasm a- 
phoresed serum from a vaccinated person 'may  
be life sa v in g ' ’.
Treatment of anthrax bio-terrorism
The Russians are reported to have bio-engineered 
an anthrax strain resistant to tetracyclines and 
penicillin1, but there is, as yet. no evidence of 
engineered quinolone resistance. The concerns 
already m entioned o f delayed germ ination of 
spores carried after exposure to the primary aero­
sol m eans that sh o rt co u rses  o f  an tib io tic
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may be insufficient. Initial treatment is 
ciprofloxacin 400mg iv 12 hourly, although in 
sensitive strains optimal treatment is with ben­
zyl penicillin as above iv. The antibiotic may be 
administered orally when the patient’s clinical 
condition improves. The total duration of therapy 
should be 60 days.
Supportive therapy if oedema is extensive may 
include corticosteroids. Other general measures 
include the prevention of septic shock and main­
tenance of fluid and electrolyte balance.
Anthrax post-exposure prophylaxis
The agent of choice is ciprofloxacin 500mg twice 
daily for 60 days. Alternatives are doxycycline 
lOOmg twice daily for 60 days or amoxycillin 
500mg three times daily for 60 days. Hart and 
Beeching have cautioned that such prophylactic 
treatment should be given only to those who re­
ally need it, since ciprofloxacin in prolonged 
courses may induce resistance in commensal 
organisms, and these in turn may transmit re­
sistance to pathogenic organisms'.
Vaccination
An anthrax vaccine consisting of an attenuated 
strain has been given to members of the US 
armed forces since 1998. Six injections are given 
over 18 months, the first three in the first month 
and aerosol challenge studies in monkeys sug­
gest complete protection at 8 weeks and 88% 
protection at 100 weeksSwartz. No serious adverse 
events have been reported but vaccine supplies 
are extremely limited. In the UK advice on the 
use of the vaccine must be obtained from the 
Public Health Laboratory Service14.
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